Loading
A phase 1/2 trial of Ipilimumab, Pembrolizumab, Nivolumab in cervical cancer and colorectal cancer, run by Neonc Technologies, Inc., now recruiting.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is a phase 1/2 interventional study registered as NCT06047379 by Neonc Technologies, Inc., with 134 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib. Conditions listed: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Merkel cell carcinoma, Nivolumab, Head and neck squamous cell carcinoma, Melanoma.
Shares Ipilimumab, Nivolumab, Melanoma, Colorectal cancer.
Shares Ipilimumab, Paclitaxel / nab-paclitaxel, Nivolumab, Carboplatin.
Shares Ipilimumab, Nivolumab, Pembrolizumab.
Shares Merkel cell carcinoma, Ipilimumab, Nivolumab, Cervical cancer.
Shares Regorafenib, Ipilimumab, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Melanoma.
Shares Ipilimumab, Nivolumab, Melanoma.